The med kit revenues are nice but minor. Enough to keep the doors open (?) but certainly not enough to finance the company's growth.
I read this deal as NNLX realizing the big potential item in their portfolio was the hydrogen technology, divesting other non-strategic IP while retaining a royalty stream and the potential to further develop that IP in other ways later.
Clearly the buzz around NNLX is all about the hydrogen technology. That is the only thing they have that could lead to a substantial upwards revaluation of the company in the market.
I doubt many are buying NNLX for the med kit stuff. I know I would not.
Market Data 
Markets 
AI
